Latest Prilenia Therapeutics News & Updates

See the latest news and media coverage for Prilenia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Prilenia Therapeutics (Prilenia)

Clinical-stage biotechnology company developing treatments for brain disorders

prilenia.com

Headquarters: Boston, United States
Founded year: 2018
Company type: Private company
Number of employees: 50–66
Industry: Biotechnology & Medical Research

Last updated October 29

Latest news about Prilenia Therapeutics (Prilenia)

In short: Prilenia advanced Phase 3 pridopidine trials in ALS and Huntington's disease amid European regulatory setbacks.

Company announcements

October 29 Prilenia

Prilenia announces publication of clinical trial data on Huntington's disease

The study links antidopaminergic medications to worsened HD progression, informing the design of the upcoming Phase 3 PRECISE-HD pridopidine trial.

October 28 Prilenia

Prilenia announces pridopidine data updates at NEALS 2026

New HEALEY Trial analysis shows positive results for ALS patients. The Phase 3 PREVAiLS study enrollment reaches 60%.

July 25, 2025 Prilenia

Prilenia and Ferrer announce CHMP pridopidine refusal for HD

The EMA’s CHMP recommends refusal of marketing authorization for Huntington’s disease. They plan to initiate a registrational HD study and Phase 3 ALS trial soon.

April 28, 2025 Prilenia

Prilenia enters collaboration with Ferrer for pridopidine

Deal worth €500M includes €125M upfront and milestones. Ferrer commercializes in Europe; Prilenia retains North America, Japan, Asia Pacific rights. Co-development for HD, ALS.

Media coverage

July 5 Finanznachrichten

Prilenia Therapeutics B.V.: Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease

PRECISE-HD (Pridopidine Phase 3 Study to Establish Clinical Impact and Safety in Huntington's Disease (HD)) is designed to further evaluate the efficacy and safety of...

April 28 Las Vegas Sun

Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer

Apr 28, 2026-- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's...

April 3 Jammin 99.9 FM

Breakthrough ALS study launches as drug aims to slow disease progression | Jammin 99.9 (WKXB FM)

The “PREVAiLS” study, which will review the investigational drug pridopidine as a potential ALS treatment, has already enrolled its first participant, according to a press...

March 30 Daily Mail

Motor neurone disease breakthrough hope as drug that can 'slow progression of ALS' starts late stage trial

Thousands of ALS sufferers could soon be given the chance at a longer life as scientists launch the final stage of a drug trial that...

Never miss news about Prilenia

Track Prilenia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Prilenia competitors & trending companies

Browse news for competitors to Prilenia and other trending companies.